38 Sidney Street
David Schenkein, MD
Agios Pharmaceuticals, Inc.
Agios (NASDAQ: AGIO) is a publicly traded biopharmaceutical company focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.
Doug Cole is on the Board of Directors.